AstraZeneca's Farxiga is approved for a new indication in China.

On August 7th, according to AstraZeneca, its first respiratory biologic drug Fasenra was officially approved in China for a new indication, for the maintenance treatment of severe eosinophilic asthma in children. Benralizumab is a precision-targeted anti-IL-5R biologic drug that targets eosinophils and was previously approved in China for maintenance treatment in adults and adolescents aged 12 and older with severe eosinophilic asthma.